Ascentage Pharma Group Stock Performance
| ASPHF Stock | USD 8.48 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.55, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Ascentage Pharma are expected to decrease at a much lower rate. During the bear market, Ascentage Pharma is likely to outperform the market. At this point, Ascentage Pharma has a negative expected return of -0.12%. Please make sure to confirm Ascentage Pharma's standard deviation, as well as the relationship between the maximum drawdown and day median price , to decide if Ascentage Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Ascentage Pharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's technical indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 1 B | |
| Total Cashflows From Investing Activities | -466.5 M |
Ascentage |
Ascentage Pharma Relative Risk vs. Return Landscape
If you would invest 932.00 in Ascentage Pharma Group on September 27, 2025 and sell it today you would lose (84.00) from holding Ascentage Pharma Group or give up 9.01% of portfolio value over 90 days. Ascentage Pharma Group is currently producing negative expected returns and takes up 2.469% volatility of returns over 90 trading days. Put another way, 22% of traded pink sheets are less volatile than Ascentage, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Ascentage Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascentage Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Ascentage Pharma Group, and traders can use it to determine the average amount a Ascentage Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0475
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ASPHF |
Based on monthly moving average Ascentage Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascentage Pharma by adding Ascentage Pharma to a well-diversified portfolio.
Ascentage Pharma Fundamentals Growth
Ascentage Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Ascentage Pharma, and Ascentage Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascentage Pink Sheet performance.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.63) % | |||
| Current Valuation | 844.8 M | |||
| Shares Outstanding | 287.77 M | |||
| Price To Book | 12.28 X | |||
| Price To Sales | 14.53 X | |||
| Revenue | 27.91 M | |||
| EBITDA | (802.15 M) | |||
| Total Debt | 1.03 B | |||
| Book Value Per Share | 3.39 X | |||
| Cash Flow From Operations | (604.68 M) | |||
| Earnings Per Share | (0.46) X | |||
| Total Asset | 2.94 B | |||
About Ascentage Pharma Performance
By analyzing Ascentage Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascentage Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascentage Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascentage Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Ascentage Pharma performance evaluation
Checking the ongoing alerts about Ascentage Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Ascentage Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ascentage Pharma generated a negative expected return over the last 90 days | |
| Ascentage Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 27.91 M. Net Loss for the year was (782.42 M) with profit before overhead, payroll, taxes, and interest of 24.58 M. | |
| Ascentage Pharma generates negative cash flow from operations | |
| About 27.0% of the company shares are held by company insiders |
- Analyzing Ascentage Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascentage Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascentage Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascentage Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascentage Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascentage Pharma's pink sheet. These opinions can provide insight into Ascentage Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascentage Pink Sheet analysis
When running Ascentage Pharma's price analysis, check to measure Ascentage Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascentage Pharma is operating at the current time. Most of Ascentage Pharma's value examination focuses on studying past and present price action to predict the probability of Ascentage Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascentage Pharma's price. Additionally, you may evaluate how the addition of Ascentage Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |